Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
FTC v. Boehringer Ingelheim Pharmace
Case Number:
12-5393
Court:
Nature of Suit:
Companies
Government Agencies
Sectors & Industries:
-
April 07, 2015
Boehringer Asks DC Circ. To Rethink Doc Ruling In FTC Probe
Boehringer Ingelheim Pharmaceuticals Inc. asked the D.C. Circuit on Monday for another shot at defending a lower court order that largely rejected the Federal Trade Commission's documents request in its investigation into an alleged Aggrenox pay-for-delay deal, arguing the circuit court's ruling slashed work product protections.
-
September 12, 2013
FTC Wants Access To Boehringer Docs In Pay-For-Delay Probe
The Federal Trade Commission told the D.C. Circuit on Wednesday that it should force Boehringer Ingelheim Pharmaceuticals Inc. to turn over documents about a $100 million drug co-promotion deal with Barr Pharmaceuticals Inc., saying the information could indicate an unlawful pay-for-delay agreement.